乳糖与低聚果糖通过糖化过程增加小鼠内脏敏感性并升高结肠黏膜肥大细胞密度
该研究在C57Bl/6小鼠中分别给予乳糖灌胃3周或含低聚果糖饲料6周,发现两种FODMAPs均增加腹部机械敏感性,伴随结肠肥大细胞数量及近端结肠上皮AGER表达升高;抗糖化剂吡哆胺可预防上述效应,且乳糖和/或吡哆胺未显著改变粪便菌群组成。
要点
- 乳糖或低聚果糖可诱导小鼠内脏高敏感,伴结肠肥大细胞增多和AGER表达升高。
- 抗糖化剂吡哆胺可预防上述内脏高敏感及肥大细胞增多。
- 乳糖和/或吡哆胺未显著改变粪便菌群组成。
核心结论
- 口服乳糖或低聚果糖可增加小鼠腹部敏感性,伴结肠肥大细胞数量及AGER表达升高,抗糖化剂可预防该效应。
研究设计与样本
- C57Bl/6小鼠随机接受乳糖灌胃(±吡哆胺)或生理盐水对照,每日一次共3周。
- 另一组小鼠接受含低聚果糖饲料(±饮用水吡哆胺)或正常饲料对照,共6周。
- 采用肌电图和机械von Frey纤维丝检测腹部敏感性,16S rRNA基因测序分析粪便菌群,组织学与免疫荧光定量肥大细胞及AGER表达。
主要发现
- 乳糖灌胃或低聚果糖饲料组小鼠较对照组腹部敏感性增加。
- 上述两组结肠肥大细胞数量增加,近端结肠上皮AGER表达升高。
- 吡哆胺可预防乳糖或低聚果糖诱导的腹部敏感性增加及肥大细胞增多。
- 乳糖和/或吡哆胺未引起粪便菌群组成的显著改变。
- 粪便羰基化合物质谱分析显示乳糖或低聚果糖组与对照组存在特征性差异。
临床怎么用
- 提示抑制糖化反应可能减轻对FODMAPs敏感的IBS患者腹痛,但尚需人体研究验证。
局限性
- 原文未报告样本量、具体P值及效应量。
- 研究为小鼠模型,结论外推至IBS患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is characterized by abdominal pain, bloating, and erratic bowel habits. A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) can reduce symptoms of IBS, possibly by reducing microbial fermentation products. We investigated whether ingestion of FODMAPs can induce IBS-like visceral hypersensitivity mediated by fermentation products of intestinal microbes in mice. METHODS: C57Bl/6 mice were gavaged with lactose, with or without the antiglycation agent pyridoxamine, or saline (controls) daily for 3 weeks. A separate group of mice were fed a diet containing fructo-oligosaccharides, with or without pyridoxamine in drinking water, or a normal chow diet (controls) for 6 weeks. Feces were collected and analyzed by 16S ribosomal RNA gene sequencing and bacterial community analyses. Abdominal sensitivity was measured by electromyography and mechanical von Frey filament assays. Colon tissues were collected from some mice and analyzed by histology and immunofluorescence to quantify mast cells and expression of advanced glycosylation end-product specific receptor (AGER). RESULTS: Mice gavaged with lactose or fed fructo-oligosaccharides had increased abdominal sensitivity compared with controls, associated with increased numbers of mast cells in colon and expression of the receptor for AGER in proximal colon epithelium. These effects were prevented by administration of pyridoxamine. Lactose and/or pyridoxamine did not induce significant alterations in the composition of the fecal microbiota. Mass spectrometric analysis of carbonyl compounds in fecal samples identified signatures associated with mice given lactose or fructo-oligosaccharides vs controls. CONCLUSIONS: We found that oral administration of lactose or fructo-oligosaccharides to mice increases abdominal sensitivity, associated with increased numbers of mast cells in colon and expression of AGER; these can be prevented with an antiglycation agent. Lactose and/or pyridoxamine did not produce alterations in fecal microbiota of mice. Our findings indicate that preventing glycation reactions might reduce abdominal pain in patients with IBS with sensitivity to FODMAPs.
引用
- Kamphuis JBJ, Guiard B, Leveque M, et al. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2019. PMID: 31711923. doi:10.1053/j.gastro.2019.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。